Overview and Scope
Acute agitation and aggression treatment refers to the medical and therapeutic interventions to manage and reduce the sudden onset of restlessness, irritability, and hostility in patients. These agitated and aggressive behaviors can be symptoms of various underlying conditions, including psychiatric disorders, neurological disorders, or substance use or withdrawal effects.
Sizing and Forecast
The acute agitation & aggression treatment market size has grown strongly in recent years. It will grow from $5.4 billion in 2023 to $5.72 billion in 2024 at a compound annual growth rate (CAGR) of 5.9%. The growth in the historic period can be attributed to advances in pharmacology, rise in clinical research, regulatory approvals, rise in prevalence of acute agitation and aggression cases, increased awareness regarding mental health .
The acute agitation & aggression treatment market size is expected to see strong growth in the next few years. It will grow to $7.23 billion in 2028 at a compound annual growth rate (CAGR) of 6.0%. The growth in the forecast period can be attributed to growing aging population, growing healthcare infrastructure, rising pharmaceutical industry investment, rise in home-base care, rise in disposable income. Major trends in the forecast period include non-pharmacological interventions, precision medicine, ai and predictive analytics, community-based support, industry collaboration.
To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/acute-agitation-and-aggression-treatment-global-market-report
Segmentation & Regional Insights
The acute agitation and aggression treatment market market covered in this report is segmented –
1) By Treatment Approach: Behavioral Approaches, Environmental Interventions, Pharmacologic Approaches
2) By Drug Class: Anti-Psychotics, Benzodiazepines, Other Drug Classes
3) By Route of Administration: Oral, Intramuscular, Other Routes of Administrations
4) By Indication: Schizophrenia, Dementia, Bipolar Disorder, Depression, Drug-Induced Agitation And Aggression, Alcohol Withdrawal, Other Indications
5) By End User: Hospitals And Ambulatory Surgical Centers, Psychiatric Care Facilities, Other End Users
Top Major Players:
Pfizer Inc
Johnson and Johnson Pvt Ltd.
F Hoffmann-La Roche Ltd.
AbbVie Inc.
Novartis AG
North America was the largest region in the acute agitation and aggression treatment market in 2023 .
North America was the largest region in the acute agitation and aggression treatment market in 2023 . Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the acute agitation and aggression treatment market market report include Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13078&type=smp
Major Driver Impacting Market Growth
The increase in the incidence of dementia is expected to propel the growth of the acute agitation and aggression treatment market going forward. Dementia refers to conditions characterized by impaired memory, cognition, and the capability to manage everyday tasks. A symptom often observed in dementia patients is agitation, manifested through behaviors such as restlessness, repetitive actions, or frequent hand movements. Acute agitation and aggression treatment play a key role in dementia. It reduces the risk of harmful symptoms, improves the patient’s quality of life, and manages the underlying cause of the agitation. For instance, in February 2023, according to the Australian Institute of Health and Welfare, an Australia-based government agency, in 2022, it was projected that about 401,300 Australians have dementia, and this figure is anticipated to be doubled to reach 849,300 in 2058. Therefore, the increase in the incidence of dementia is driving the growth of the acute agitation and aggression treatment market.
Key Industry Players
Major companies operating in the acute agitation and aggression treatment market market include Pfizer Inc., Johnson and Johnson Pvt Ltd., F Hoffmann-La Roche Ltd, AbbVie Inc., Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, GlaxoSmithKline plc., Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co Ltd., Mylan NV, Biogen Inc., Bausch Health Companies Inc., UCB SA, Servier Laboratories, Sun Pharmaceutical Industries Ltd, AstraZeneca PLC, Ono Pharmaceutical Co Ltd, Apotex Inc., H Lundbeck A/S, Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Neurocrine Biosciences Inc, Aurobindo Pharma Limited, Alkermes plc., Indivior plc., Sunovion Pharmaceuticals Inc., Vanda Pharmaceuticals Inc., and Alexza Pharmaceuticals Inc
The acute agitation and aggression treatment market report table of contents includes:
1. Executive Summary
2. Acute Agitation And Aggression Treatment Market Characteristics
3. Acute Agitation And Aggression Treatment Market Trends And Strategies
4. Acute Agitation And Aggression Treatment Market – Macro Economic Scenario
5. Global Acute Agitation And Aggression Treatment Market Size and Growth
…
31. Global Acute Agitation And Aggression Treatment Market Competitive Benchmarking
32. Global Acute Agitation And Aggression Treatment Market Competitive Dashboard
33. Key Mergers And Acquisitions In The Acute Agitation And Aggression Treatment Market
34.Acute Agitation And Aggression Treatment Market Future Outlook and Potential Analysis
35. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
